All Episodes
Medical Digest & Congress Report — 736 episodes
Control the modifiable risk factors to prevent dementia: Insights from the 10/66 studies
The New Landscape of Alzheimer’s Therapy: Targets, Treatments, and Future Outlook
Highlights of ISTH Guidelines and Guidance Documents - report from ISTH 2026
Updated recommendations on the diagnosis and classification of FXIII deficiencies / ISTH 2026 Diagnostic Highlights
Future Anticoagulants - report from ISTH 2026
Anticoagulant Associated Bleeding: Specific Populations and Reversal - report from ISTH 2026
Acute and Long-Term Management of Severe DVT by ESVM VTE Guideline - report from ISTH 2026
Introductions to the ISTH Guidelines and Guidance Documents - report from ISTH 2026
Cancer-Associated Thrombosis & Hemostasis - report from ISTH 2026
VTE Diagnosis: What's New? - report from ISTH 2026
Novelties in the Treatment of Alzheimer's Disease
Highlights of the AAIC 2026 Congress
Targeting CD19+ B-Cells in IgG4-Related Disease: Clinical Evidence and Implications for Long-Term Management - Report from EULAR 2026
State-of-the-Art Treatment in Psoriatic Arthritis - Report from EULAR 2026
The RA Paradigm Shift: New Insights into Pathogenesis and a Pipeline of Promise - Report from EULAR 2026
Systemic Sclerosis: Deciphering Pathogenesis, Unveiling Comorbidities, and Paving the Way for Targeted Treatment - Report from EULAR 2026
EULAR / ACR Classification Criteria for Anti-Synthetase Syndrome - Report from EULAR 2026
Workflow in Focus: Advancing Global Health in Rheumatology - Report from EULAR 2026
Diagnosing Osteoporosis in Inflammatory Rheumatic Conditions - Report from EULAR 2026
Biosimilars in Focus: Advancing Global Health in Rheumatology - Report from EULAR 2026
Treating Hypertension in the Elderly: Insights from the ESH Congress
Screen, Monitor and Manage CTD-ILD: Practical Application of ERS/EULAR Guidelines and Expert Insights - Report from EULAR 2026
Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease - Report from EULAR 2026
Promote Happiness: Rethinking Care for Brighter Outcomes in Older Adults with RMDs - Report from EULAR 2026
Improving Care in Spondyloarthritis: A Multidisciplinary Approach to the Disease and Its Extra-Musculoskeletal Manifestations - Report from EULAR 2026
HPR Sessions at EULAR 2026
The Patient is in the Middle - Report from EULAR 2026
Secukinumab in Polymyalgia Rheumatica: Results of the Phase 3 REPLENISH Trial - Report from EULAR 2026
No Pain is THE Gain in Rheumatoid Diseases - Report from EULAR 2026
Unveiling Novel Antibodies and Their Practical Implication in RMDs - Report from EULAR 2026
HPR: Patient Education, Support and Improving Access to Rheumatology Care - Report from EULAR 2026
Pain Management in Rheumatological Diseases - Report from EULAR 2026
Managing Comorbidities in Systemic Sclerosis to Achieve Better Outcome - Report from EULAR 2026
Managing Comorbidities in Rheumatoid Arthritis for Better Outcome - Report from EULAR 2026
Novel Development in Treatment of Lupus - Report from EULAR 2026
Impact of Sonelokimab on Clinical and Imaging Outcomes in Axial Spondyloarthritis: Results of a Phase 2 Study - Report from EULAR 2026
From Diagnosis to Family Building: Navigating Fertility in RMDs - Report from EULAR 2026
Novel Treatment Horizons in Lupus: Key Updates from EULAR 2026
Highlights of EULAR 2026
Chest HRCT in Detecting, Staging and Follow Up of SARD-ILD - Report from EULAR 2026
Clinical Manifestations and Disease Course in Systemic Sclerosis - Report from EULAR 2026
Under the Surface: New Perspectives in Lupus with TLR7/8 Inhibition - Report from EULAR 2026
Transitioning Young Patients with Autoinflammatory Diseases to Adult Care: Implications for Daily Clinical Management - Report from EULAR 2026
Advanced Management in Rheumatoid Arthritis: Critical Updates from EULAR 2026
Tired Is Not Just a State of Mind: Addressing Pathological Fatigue at EULAR 2026
Assessment of Disease Activity in Psoriatic Arthritis - Report from EULAR 2026
The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide
Lymphoma Highlights and Key Takeaways from the 2026 ASCO Annual Meeting
Immunotherapy in Early-Stage Breast Cancer - Report from ESMO BC 2026
The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer - Report from ESMO BC 2026
Highlights and key takeaways from the 2026 EPA Congress
Efficacy and Safety of Sotatercept in PH-HFpEF: Results From the Phase 2 CADENCE Trial - report from ACC 2026
Therapeutic Novelties in the New ACC 2026 Acute Pulmonary Embolism Guideline
Human Challenge Models: A New Gold Standard? - Report from WVCDC 2026
The INSIS Metacohort Vaccine Safety Study: A Paradigm for Clinical and Immune AEFI Profiling - Report from WVCDC 2026
Building a Future of Vaccine Trust Through Transparency and Innovation - Report from WVCDC 2026
Prove it's safe: Is this the new vaccine policy "norm?" - Report from WVCDC 2026
Combining Respiratory Vaccines - Balancing Efficacy, Durability and Immunization Schedules - Report from WVCDC 2026
Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction - report from ACC 2026
Meet the Experts: 2025 High Blood Pressure Guideline - report from ACC 2026
2026 Acute Pulmonary Embolism Guideline
Meet the Experts: 2025 High Blood Pressure Guideline - report from ACC 2026
Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension - report from ACC 2026
Pulmonary Embolism in 2026: A Case-Based Journey From Diagnosis to Recovery - report from ACC 2026
Mavacamten in Symptomatic Adolescent Patients With Obstructive HCM: Results From the Phase 3 Scout-HCM Trial - report from ACC 2026
Saving Women's Hearts - report from ACC 2026
Highlights of the 2026 ACC/AHA Dyslipidemia Guideline
An Update on Cardiac Prevention Medications: Hypertension and Incretin in Focus - report from ACC 2026
Effects of Tirzepatide vs. Dulaglutide on Cardiorenal Outcomes: SURPASS-CVOT Analysis - report from ACC 2026
Next-Generation Lipid Treatment Options - report from ACC 2026
Fine tuning prostate cancer diagnostics - report from EAU 2026
Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI - report from ACC 2026
Interventional Cardiology Highlights of ACC.26
Efficacy and Safety of Enlicitide Decanoate: Results from the Phase 3 CORALreef AddOn Trial - report from ACC 2026
Highlights of ACC.26
2026 Acute Pulmonary Embolism Guideline
Cutting-edge strategies in bladder cancer: Trials, techniques, and predictive tools - report from EAU 2026
MIBC - There is a gender bias in bladder cancer diagnosis and treatment - Women experience delays, misdiagnosis, worse outcomes - report from EAU 2026
Guidelines Controversies - Paeds and MIBC - report from EAU 2026
Adaptive recurrence risk predictions to optimise prostate cancer follow-up: Results of model validation and clinical impact - report from EAU 2026
The role of urine biomarkers in detection of bladder cancer - report from EAU 2026
Urology trials in bladder and prostate cancer - report from EAU 2026
Cutting-edge strategies in bladder cancer: Trials, techniques, and predictive tools - report from EAU 2026
Redefining EMBARK-like Patients in the PSMA Era: Impact of PSMA-PET Restaging on Disease Classification and Management - report from EAU 2026
Progression-free survival following primary staging with [¹⁸F]PSMA-1007 PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA PET randomized controlled trial
2026 EAU Guidelines update and controversies – Urolithiasis, female and male LUTS and infections: What has changed?
Infections: Prophylactic antibiotics in renal cancer surgery - Safeguarding patients from postoperative infection - report from EAU 2026
Antibiotics & renal health: Striking the perfect balance between benefit and risk - report from EAU 2026
Navigating the future of urologic care - report from EAU 2026
From MRI to Post-treatment care: prostate cancer screening - report from EAU 2026
Prostate cancer: PARPIs finally explained - report from EAU 2026
Retroperitoneal lymph dissection considerations in testicular cancer - report from EAU 2026
How imaging is shaping prostate cancer management: Screening and early detection - report from EAU 2026
Advancing BPO treatment: From aquablation to enucleation - report from EAU 2026
Kidney stones made simple: Best clinical practice and preventing complications - report from EAU 2026
Kidney stones made simple: A comprehensive update for all urologists - report from EAU 2026
Navigating the future of urologic care: Trials in progress - report from EAU 2026
How imaging is shaping prostate cancer management - report from EAU 2026
Increasing role of triple therapy in COPD - report from IWLH 2026
Redefining epithelial driven airway inflammation: insights from clinical experience with Tezepelumab - report from IWLH 2026
How should COPD disease characteristics guide therapeutic decisions?
How to improve the management of newly diagnosed asthma? - report from IWLH 2026
Adult Cystic Fibrosis - report from IWLH 2026
Clinical remission of asthma: from biologics to inhaled drugs - report from IWLH 2026
Treatment response trajectories to biologics for severe eosinophilic asthma and achievement of clinical remission - report from IWLH 2026
New Trajectories in Lung Cancer - report from IWLH 2026
Vaccinating respiratory patients: a new landscape - report from IWLH 2026
Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial
Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers
Program Director's Choice from SABCS2025 - Part 1 : Giredestrant Improves Disease-free Survival in Patients With Early-stage Breast Cancer in Phase III lidERA Trial
Highligths of SABCS 2025
Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia - report from ASH 2025
Lymphoma and CLL highlights of the ASH 2025
Quadruplet Therapy in Multiple Myeloma - report from ASH 2025
Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL - report from ASH 2025
Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL - report from ASH 2025
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials - report from ASH 2025
Symptom-based progression-free survival as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the ALPINE trial
Azacitidine–Venetoclax Combination Outperforms Standard Care in Acute Myeloid Leukemia Patients Eligible for Intensive Chemotherapy - report from ASH 2025
What's new in myeloma? - report from ASH 2025
Novelties in Acute Myeloid Leukemia at ASH2025
State of the art treatment of Chronic Myeloid Leukemia - report from ASH 2025
Myelodysplastic Syndrome Highlights from ASH 2025
COBRA trial and other novelties in multiple myeloma at ASH 2025
Multiple Myeloma Highlights from ASH 2025
Diagnosis and Management of Cold Agglutinin Disease - report from ASH 2025
Breakthrough in the treatement of Multiple Myeloma - report from ASH 2025
Novelties in Diffuse Large B-cell Lymphoma at ASH2025
First-of-Its-Kind Phase 3 Trial Shows Pirtobrutinib Is Noninferior to Ibrutinib in Treatment-Naïve CLL - report from ASH 2025
New findings support a chemo-free approach for treating Ph+ ALL - report from ASH 2025
Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia - report from ASH 2025
Bispecific Combo May Offer “Functional Cure” in Multiple Myeloma - report from ASH 2025
Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma - report from ASH 2025
Novelties in Follicular Lymphoma at ASH2025
Remote BP Monitoring and Drug Titration – Does it work? How do we do it? - report from AHA 2025
Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis
Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure - report from AHA 2025
DASH-Patterned Groceries Reduce Blood Pressure - report from AHA 2025
TUXEDO-2: Ticagrelor vs. Prasugrel in Patients With Diabetes and Multivessel Disease After PCI - report from AHA 2025
Aldosterone and Mineralocorticoid Receptors: New Paradigms and Novel Therapies - report from AHA 2025
Navigating AHA Scientific Statements: Advancing Evidence-Based Cardiovascular Care - report from AHA 2025
A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial - report from AHA 2025
First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides - report from AHA 2025
Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure - report from AHA 2025
Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial
Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial - report from AHA 2025
Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation - report from AHA 2025
Highlights of AHA / ACC Blood Pressure Management Guideline
POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With HFrEF - report from AHA 2025
SOTA-P-CARDIA Trial: A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes - report from AHA 2025
The Clinicians view on the 2025 Guideline for Acute Coronary Syndromes - report from AHA 2025
The New 2025 Guideline for Acute Coronary Syndromes: The European perspective - report from AHA 2025
State of the art tumor-targeting IL-12 immunocytokine therapies - report from SITC 2025
Reprogramming the Immune Microenvironment to Intercept Lung Adenocarcinoma Precancer - report from SITC 2025
Primary analysis of patients with high-risk localized, locally recurrent, or regionally advanced cutaneous squamous cell carcinoma treated with neoadjuvant PD-1 therapy - report from SITC 2025
Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma - report from SITC 2025
How to optimize PD1/PDL1 treatment? - report from SITC 2025
Modulating the Tumor Microenvironment with T Cell Bispecifics - report from SITC 2025
Comparative Cardioprotective Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Pulmonary Arterial Hypertension: Insights from a Large-Scale Real-World data analysis
Ensifentrine treatment improves COPD symptoms and quality of life in a pooled analysis of the ENHANCE trials - report from CHEST 2025
Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s - report from CHEST 2025
Advances in the Development of Therapeutic Targets in the Platelet for Prevention of Thrombosis - report from AHA 2025
Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial - report from AHA 2025
2025 AHA Blood Pressure Guideline & CKD Management: Key Insights and Global Perspectives - report from AHA 2025
Lipid Lowering Therapies and Lipid Risk Factors - report from AHA 2025
The New 2025 Guideline for Acute Coronary Syndromes - report from AHA 2025
Aortic Regurgitation: The New Frontier - Imaging, Interventions, and the Future of Treatment - report from AHA 2025
Immuno-oncology biomarkers in locally advanced HNSCC - lessons from the KeyNote-689 trial - report from ESMO 2025
Novelties of the treatment of colon cancer at ESMO 2025
How to PROC - Breaking the Wall of Platinum-Resistance in Ovarian Cancer - report from ESMO 2025
IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC - report from ESMO 2025
T-DXd Effective for Treating HER2+ Advanced or Metastatic Breast Cancer, Regardless of Treatment History, HR Status, or PIK3C Mutations - report from ESMO 2025
What's new in ESMO guidelines? - report from ESMO 2025
DYNAMIC-III trial results: ctDNA blood test is a powerful tool to guide treatment choices for people with advanced colon cancer - report from ESMO 2025
Overcoming Therapeutic Challenges in High-risk Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Approach - report from ESMO 2025
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials - report from ESMO 2025
Durvalumab in Combination with BCG for BCG-Naïve High-Risk NMIBC: Final Analysis of the Phase 3, Open-Label, Randomized POTOMAC Trial - report from ESMO 2025
Treatment Landscape in Resectable LA HNSCC - report from ESMO 2025
Analysis of Second Primary Cutaneous Squamous Cell Carcinoma Tumors Reported During the C-POST Trial - report from ESMO 2025
Unlocking the potential of radioligand therapy for advanced prostate cancer - report from ESMO 2025
Thoracic oncology - Lung cancer screening updates: switch gears to move forward - report from ERS 2025
Advancing lung cancer care with real-world evidence, artificial intelligence and computerised clinical guidelines - report from ERS 2025
Horizon scanning in the treatment of interstitial lung diseases- report from ERS 2025
Addressing the generational challenge in lung health amidst the growing number of novel tobacco products - report from ERS 2025
The emerging therapeutic interventions for the management of interstitial lung diseases - report from ERS 2025
Current controversies in interstitial lung diseases - report from ERS 2025
Prevention in action: prevention in the joint action on respiratory disease - report from ERS 2025
Understanding aging mechanisms and their effect in asthma - report from ERS 2025
Lung cancer and severe respiratory comorbidities: navigating complex clinical challenges - report from ERS 2025
Benefits of twice daily inhaler dosage in the treatment of COPD - report from ERS 2025
Real-life effectiveness of aclidinium/formoterol in COPD control: preliminary results of the REDACT observational study - report from ERS 2025
Severe asthma: from the underlying mechanism to clinical remission - report from ERS 2025
Unlocking new pathways: emerging therapeutic targets in asthma and COPD - report from ERS 2025
Epidemiology of asthma, including severe asthma - report from ERS 2025
Unmasking COPD: Recognizing Early Signs and Tailoring Treatment - report from ERS 2025
Novelties in hypertension at ESC 2025
Evolution of anticoagulation therapy in patients with atrial fibrillation - report from ESC 2025
Cardiac myosin inhibitors in the daily practice - report from ESC 2025
Kidney function and coronary artery disease - lessons from the EUROASPIRE IV and V studies
2025 ESC Guidelines for the Management of Cardiovascular Disease and Pregnancy
New insights in the management of hypertrophic cardiomyopathy: exploring the clinical spectrum - report from ESC 2025
2025 ESC Consensus Statement on Mental Health and Cardiovascular Disease
The importance of influenza vaccination in older people - report from ESC 2025
2025 ESC Guidelines for the Management of Myocarditis and Pericarditis
2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
The importance of early detection and diagnosis of dementia
Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations
What is New in systemic lupus erythematosus?
How to treat elevated TG in other high risk patients - report from WCCL 2025
The lower the better: never mind future drugs, use what you have available to fullest extent and lower cardiovascular risk aggressively - report from WCCL 2025
How to treat elevated Lp(a) - report from WCCL 2025
What clinicians must know about diabetic dyslipidemia - report from WCCL 2025
How to implement LDL guidelines? - report from WCCL 2025
Newborn Screening for Atherosclerosis Risk? - report from WCCL 2025
What will change in the lipid lowering landscape in the next 5 years? - report from WCCL 2025
Diabetic Dyslipidemia: Beyond LDL – Atherogenic Lipoproteins in Focus - report from WCCL 2025
LDL lowering in 2025: Optimal approach - report from WCCL 2025
POLARGO Trial Shows OS Benefit with Pola-R-GemOx in Transplant-Ineligible R/R DLBCL - report from EHA2025
Asciminib in the treatment of CML - report from EHA2025
AML Highlights from EHA 2025
Advances in Post-Covalent Bruton`s Tyrosine Kinase Inhibitor Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia - report from EHA2025
Frontline Therapy of B-cell Acute Lymphoblastic Leukemia: Harnessing Innovative Approaches to Improve Outcomes - report from EHA2025
Diffuse large B cell lymphoma: Bispecifics in focus - report from EHA2025
How to educate haematologists to better identify Gaucher disease? - report from EHA2025
Management of Multiple Myeloma at EHA 2025
Highlights of Diffuse Large B-Cell Lymphoma at EHA 2025
Emerging Insights in the Secondary Acute Myeloid Leukemia in 2025 - report from EHA2025
Combination Therapy For The Treatment Of Hypertension - report from ESH2025
The Role of CAR T-cell Therapy in Multiple Myeloma - report from EHA2025
Multiple Myeloma update at EHA 2025
Shaping the Treatment Landscape in Myelodysplastic Syndromes and Acute Myeloid Leukemia - report from EHA2025
New therapeutic options and translational insights in ALL - report from EHA2025
Exploring the Landscape for FLT3-mutated Relapsed/Refractory Acute Myeloid Leukaemia - report from EHA2025
How to Improve the Awareness in Gaucher Disease? - report from EHA2025
Mapping the Evolving Chronic Lymphocytic Leukemia Treatment Landscape for the Optimal Patient Journey and Experience - report from EHA2025
Optimising the Management of FLT3mut+ R/R AML - report from EHA2025
ALL Highlights from EHA 2025
First-Steps With Time-Limited BTKi-B–cell lymphoma 2 Inhibitor Options in Treatment Naïve CLL - report from EHA2025
Improving Patient Outcome in Secondary Acute Myeloid Leukemia in 2025 - report from EHA2025
The Second Coming of Finite Therapy in Chronic Lymphocytic Leukemia - report from EHA2025
The Unprecedented Progress on the Treatment of Relapsed and Refractory Multiple Myeloma in 2025 - report from EHA2025
Honorary President's take on the highlights of ESH 2025 meeting - report from ESH2025
Build a strong therapeutic alliance with your patient: with a little help from your friends - report from ESH2025
Let’s target success for every patient: Achieving blood pressure control in high-risk patients - report from ESH2025
Patients and doctors’ partnership: Should we change the paradigm to improve blood pressure control? - report from ESH2025
Cracking the code of resistant hypertension: From challenges to solutions - report from ESH2025
Combining vaccines is the future of vaccination - report from WVCDC 2025
Addressing the burden of long Covid: reaching a global consensus - report from WVCDC 2025
Benefits and challenges of combining vaccines - report from WVCDC 2025
Which vaccination programs with pandemic potential have worked and what else can be done to repurpose COVID facilities and incorporate novel platforms? - report from WVCDC 2025
Clinical Updates for a novel preventative breast cancer vaccine - report from WVCDC 2025
Cell-Based Therapeutic Vaccination as Adjuvant Therapy for MGMT Unmethylated Glioblastoma - report from WVCDC 2025
Intranasal Universal Influenza Vaccine: Promising Data on Blocking Virus Transmission - report from WVCDC 2025
Highlights of ACC.25
Chronic Coronary Disease Management in 2025: What's New in the Guidelines? - report from ACC.25
Arrhythmia Management: Updates From Recent Practice Guidance Documents - report from ACC.25
Chief Medical Officer's take on ACC.25
Why lipoprotein(a) matters for clinical decisions and patient risk? - report from ACC.25
Discussion on Optimizing Hypertension Management: We Need New Treatment and Interventions - report from ACC.25
Lifetime Benefit by Control of Modifiable Risk Factors - report from ACC.25
Dapagliflozin Reduced LVMI in Patients with CKD : DECODE-CKD - report from ACC.25
Nurse-led behavior changes after heart attack cut subsequent event risk by 30% - report from ACC.25
Lorundrostat shows continued promise against uncontrolled hypertension - report from ACC.25
Shifting the Paradigm: Lipoprotein(a) in Cardiovascular Disease - report from ACC.25
ALIGN-AR reports positive outcomes with dedicated TAVI device for aortic regurgitation - report from ACC.25
From Evidence Generation to Implementation: Tackling Unmet Need in ASCVD - report from ACC.25
Stepping into the future of care for patients with peripheral artery disease with the 2024 guidelines - report from ACC.25
Intravenous iron offers some benefits for some patients with heart failure - report from ACC.25
Semaglutide improves walk distance for PAD patients with diabetes - report from ACC.25
TAVR comparable to open heart surgery after 5 years in low-risk patients - report from ACC.25
Oral semaglutide reduces cardiovascular events by 14% at four years - report from ACC.25
Research shows clopidogrel as better long-term therapy than aspirin after PCI - report from ACC.25
Low-dose apixiban comparable to full dose for preventing VTE recurrence in patients with cancer - report from ACC.25
WARRIOR study: Intensive medical therapy does not help or harm women with chest pain - report from ACC.25
Redefining Risk of Recurrence: Latest advances with CDK4/6 inhibitors in HR+/HER2− early breast cancer
Why there is no such thing as a psychiatric diagnosis?
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis
Social cognition in autism and ADHD
Addressing Comorbid Bipolar Disorder and ADHD
Management of Multiple Myeloma at ASH 2024
Highligths of SABCS 2024
Early Breast Cancer Updates - report from SABCS2024
CLL Highlights from ASH 2024
The Aymara Gene: A Tale of High Altitude and Human Evolution - report from ASH2024
State of the Art Treatment in Polycythemia Vera - report from ASH2024
State of the Art Treatment in Myelofibrosis - report from ASH2024
Do GLP-1s Lower VTE Risk in People With Type 2 Diabetes? - report from ASH2024
24-hour Urine Testing does not Add Value to Multiple Myeloma Response Assessments - report from ASH2024
Bridging Gaps in Multiple Myeloma Care: A Community Oncologist's Guide to Navigating the Evolving Treatment Landscape - report from ASH2024
Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms - report from ASH2024
State of the Art Treatment in Adult ALL - report from ASH2024
State of the Art Treatment in Lymphoma - report from ASH2024
Mastering the Art of Myelofibrosis Care: Expert Guidance, Clinical Experience, & Innovation for More Personalized Disease Control - report from ASH2024
Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - report from ASH2024
Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia - report from ASH2024
State of the Art Treatment in Myelodysplastic Syndromes - report from ASH2024
Five-Year Analysis of the POLARIX Study - report from ASH2024
Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR-Ts - report from ASH2024
Unraveling Data and Care Strategies for AL Amyloidosis - report from ASH2024
Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma - report from ASH2024
Smoking Tied to Worsened Disease Progression in Myelodysplastic Syndromes - report from ASH2024
Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - report from ASH2024
Estrogen Receptor Mutations in HR+ Advanced Breast Cancer: Next-Generation Practice Recommendations on Mutation Screening to Guide Therapeutic Decisions - report from SABCS2024
Anthracyclines May Improve Survival in High-Risk Breast Cancer, But Risks Must Be Weighed - report from SABCS2024
Immunotherapy: Explore Inroads for ER-positive Disease, Challenges Ahead - report from SABCS2024
The Winding Road of Immune Biomarkers in Early Breast Cancer - report from SABCS2024
Palbociclib Plus Endocrine Therapy Beats Chemo in HR+/HER2− Metastatic Breast Cancer - report from SABCS2024
COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS - report from SABCS2024
Palbociclib Shows Benefit in HR+ HER2+ Metastatic Breast Cancer – the PATINA Trial - report from SABCS2024
Breast Cancer in Young Women - report from SABCS2024
The Future of Cancer Genetics Is Here - Reversion Mutations in BRCA1/2 in Response to Therapy - report from SABCS2024
Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy - report from SABCS2024
Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies - report from SABCS2024
Risk Reduction and Early Detection: Updates on Breast Cancer Screening - report from SABCS2024
Efficacy and Safety of Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy by Pace of Disease Progression on Prior Endocrine-based Therapy - report from SABCS2024
Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer - report from SABCS2024
Immediate Surgery Lowers Local Recurrence in Older Breast Cancer Population - report from SABCS2024
PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial - report from SABCS2024
Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma - report from ASH2024
Blinatumomab in Combination With Chemotherapy May Improve Survival in Pediatric Patients Newly Diagnosed With B-Cell Precursor ALL - report from ASH2024
Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR-Ts - report from ASH2024
High-Fiber NUTRIVENTION Study for Delaying Progression of Myeloma - report from ASH2024
Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial - report from ASH2024
Escape the Amyloid Maze: Unraveling Data and Care Strategies for AL Amyloidosis - report from ASH2024
How to improve immunization in children and adolescents? - report from CHEST2024
New developments in neurendocrine tumours
Duchenne Muscular Dystrophy, Then and Now: Lessons from Respiratory Medicine - report from CHEST2024
Update in Vaccines for RSV, COVID, Influenza - report from CHEST2024
How to manage acute PE? Follow the five D! - report from CHEST2024
Breathing Easier: The Evolution and Future of Asthma Care - report from CHEST2024
Importance of Vaccinations for Patients With Pulmonary Conditions - report from CHEST2024
Comparison of GINA and EPR-4 Asthma Guidelines - report from CHEST2024
New directions in Asthma and COPD - report from CHEST2024
Interplay of Pregnancy and Sleep - report from CHEST2024
Evaluation and Management of VTE in Pregnancy - report from CHEST2024
Beyond Bronchodilators: Bronchoscopic Management of COPD - report from CHEST2024
Portopulmonary Hypertension: How Should We Think About it? - report from CHEST2024
Hemodynamic Assessment in Pulmonary Arterial Hypertension - Obtaining the Most Out of Right Heart Catheterization - report from CHEST2024
The role of LABA/LAMA and triple therapy for patients with COPD in GOLD Group E - report from CHEST2024
CHEST Guidelines on Biologics for Severe Asthma: Evidence, Recommendations, and Clinical Implications - report from CHEST2024
Advanced Management Strategies in Severe Asthma and COPD - report from CHEST2024
Lymphoma highlights of the ESMO 2024 Congress
Quadruplet therapy is becoming the new standard of treatment - Multiple myeloma highlights at ESMO2024
Melanoma highlights of the ESMO 2024 Congress
Radiation therapy for breast cancer can be safely shortened by changing technique - report from ESMO2024
Prostate Cancer highlights of ESMO 2024 Congress
Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor - report from ESMO2024
RCC highlights of ESMO 2024 Congress
Breast cancer, metastatic highlights of the ESMO 2024 Congress
Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in Previously Treated HER2-positive mBC Including a Large Cohort of Patients with Brain Metastases
Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer - report from ESMO2024
Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial Carcinoma - report from ESMO2024
Biomarker selected strategies and immunotherapy change the landscape of upper GI tumor treatment - report from ESMO2024
Rise of cancer in young adults - lower GI news from ESMO2024
Eyes to the future: Moving towards molecular and AI-driven oncology - report from ESMO2024
Incorporating novel treatment insights for ER+ early BC patients
Novel targeted therapies for pancreatic cancer - report from ESMO2024
Systemic therapy for organ preservation - report from ESMO2024
The Rome Trial From Histology to Target: the Road to Personalize Targeted Therapy and Immunotherapy - report from ESMO2024
Genitourinary tumours, non-prostate highlights of the ESMO 2024 Congress
Lung cancer interception: New approaches to lung cancer screening and prevention - report from ESMO2024
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib + Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma - report from ESMO2024
Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE - report from ESMO2024
PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer - report from ESMO2024
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study
POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC - report from ESMO2024
Setting a new benchmark for ALK+ aNSCLC targeted therapy - report from ESMO2024
Breast cancer, early stage highlights of the ESMO 2024 Congress
Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup - report from ESMO2024
Treatment of cervical cancer in 2024 in the highlight of KEYNOTE-A18 study - report from ESMO2024
New pillars of optimal medical treatment in heart failure - report from ESC2024
Highlihts of ERS 2024 - The President's perspective
Why is idiopathic pulmonary fibrosis not so idiopathic? - report from ERS2024
Improving Lung Health in the 21st century - report from ERS2024
Overcoming the challenges of increasing urbanisation for respiratory health - report from ERS2024
Thoracic oncology - Lung cancer diagnostics and treatment challenges - report from ERS2024
Novel research data on asthma and chronic obstructive pulmonary disease management: clinical applications - report from ERS2024
COPD in a nutshell at ERS2024
Paediatric asthma in 2024: from prevention to transition - report from ERS2024
How to change urban areas to improve the life of allergic patients? - report from ERS2024
Paediatric asthma in 2024: from prevention to transition - report from ERS2024
Smoke-free Europe: utopia or feasible reality? - report from ERS2024
Respiratory Medicine against Lung Cancer - report from ERS2024
What is the benefit of starting earlier PCSK9 inhibitors for acute coronary syndromes? - report from ESC2024
Pre-diabetes: a risk factor for cardiovascular disease? - report from ESC2024
Patient engagement in lipid-lowering therapies - report from ESC2024
Guidelines in Practice: implementing the 2023 Focused Update on Heart Failure - target, treat, and titrate - report from ESC2024
Cardiovascular multimorbid patients’ care - report from ESC2024
2024 ESC Guidelines for the Management of Atrial Fibrillation - report from ESC2024
2024 ESC Guidelines for the Management of Chronic Coronary Syndromes - report from ESC2024
EPIC-CAD - Edoxaban monotherapy vs. dual antithrombotic therapy for atrial fibrillation and stable coronary artery disease - report from ESC2024
FINE-HEART - Participant-level pooled analysis of finerenone in heart failure and chronic kidney disease trials - report from ESC2024
Chronic ischaemic syndrome management in 2024: are we ready for the (r)evolution? - report from ESC2024
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis - report from ESC2024
Guidelines in Practice: cardio-renal protection in patients with diabetes - report from ESC2024
2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases - report from ESC2024
The Dundee experience: really personalised acute stroke treatment! - report from ESC2024
Beta blocker interruption in patients with prior myocardial infarction: results of the ABYSS trial and effect on blood pressure and heart rate control - report from ESC2024
ESC Clinical Practice Guidelines 2022 and 2023 for General Practice and General Cardiology: where do we stand? - report from ESC2024
Patient with diabetes, heart failure with reduced ejection fraction, and impaired kidney function: how to implement the guidelines and take-home messages - report from ESC2024
Clash of the titans: when cardiovascular and kidney diseases overlap - report from ESC2024
Chronic coronary syndrome: the journey so far and the road to the future - report from ESC2024
Clinical trial updates on the GLP-1 receptor agonists - report from ESC2024
QUADRO - A single 4-drug combination in hypertension - report from ESC2024
The importance of the anterior interface in eye surgery
How to treat atherosclerosis? - Highlights of the EAS 2024 (Part II)
How to treat atherosclerosis? - Highlights of the EAS 2024 (Part I)
75th Anniversary of Glucocorticoids - what have we learnt? - report from EULAR2024
Early and maintained comparative effectiveness of 5 different classes of advanced therapies in a large multinational cohort of real-world PsA patients - report from EULAR2024
Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024
What is New : Osteoporosis in Rheumatology - report from EULAR2024
Interstitial Lung Disease: from diagnosis to management - report from EULAR2024
Promising directions in the treatment of Psoriatic Arthritis - report from EULAR2024
Update of EULAR recommendations for the treatment of Systemic Sclerosis - report from EULAR2024
Lupus: what's on the horizon? - report from EULAR2024
Secukinumab versus standard-of-care in axial spondyloarthritis - report from EULAR2024
Difficult Questions in Osteoporosis - report from EULAR2024
Update on EULAR/ACR Project: Risk Stratification in patients with arthralgia suspicious for progression to RA - report from EULAR2024
Cardiovascular Comorbidities of Rheumatic and Musculoskeletal Diseases - report from EULAR2024
Fatigue, Pain and Opioids in Rheumatological Diseases - report from EULAR2024
Asymptomatic ultrasonographic urate deposition in the joint - are there long-term consequences? - report from EULAR2024
Cardiovascular Risk in Rheumatic & Musculoskeletal Disease - report from EULAR2024
"Asymptomatic" Hyperuricemia: Innocent bystander or menacing foe? - report from EULAR2024
Rheumatoid Arthritis Prevention: what have we learnt, and where do we go next? - report from EULAR2024
Metabolic Reprogramming in Autoimmunity - report from EULAR2024
Overview of the 2024 EAS Congress
Combination of a beta-blocker with calcium channel blocker in hypertension - report from ESH2024
2023 ESH Hypertension Guideline Update - report from ESH2024
ESH - ESC HFA Joint meeting: HFpEF update 2024 - report from ESH2024
ESH guidelines 2023: a new light on beta-blockers in hypertension - report from ESH2024
Management of older hypertensive patients - report from ESH2024
Controlling the uncontrollable - resistant hypertension and the role of aldosterone - report from ESH2024
How lifestyle affects hypertension - report from ESH2024
ESH - ISH Joint Session: Balancing common side effects of Thiazide/Thiazide-like diuretics through addition of other Blood Pressure lowering drugs - report from ESH2024
Beta-blockers in hypertension and CVD - report from ESH2024
Diabetes and Metabolic risk factors - report from ESH2024
Nephroprotection using SGLT2 inhibitors in patients with hypertension - report from ESH2024
ESH Clinical Practice Guidelines - report from ESH2024
Haematology is at the forefront - interview with EHA President
Obesity induced hypertension - report from ESH2024
Effect of renal denervation on blood pressure in patients with chronic kidney disease and uncontrolled hypertension - report from ESH2024
Hypertension and beta-blocker choice: influence of age, stress, and co-morbidities - report from ESH2024
Overcoming the resistance - Is renal denervation the solution? - report from ESH2024
One heart and two kidneys: Promoting organ protection using SGLT-2 inhibitors in patients with hypertension - report from ESH2024
Why is it so difficult to reach the expected BP target in real-life patients? - report from ESH2024
Time to act to improve adherence in hypertension management: bridging the gap between knowledge and action - report from ESH2024
Real-life hypertensive patients: Towards a holistic approach in clinical practice - report from ESH2024
Hypertension and CAD: need of more SPCs - report from ESH2024
Challenges in hypertension adherence to treatment - report from ESH2024
HPV-associated head and neck cancers - report from Danube Symposium
Breakthroughs and challenges in the treatment of head and neck cancer - report from Danube Symposium
Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements - report from ACC2024
Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise - report from ACC2024
Late Breaking Clinical Trial on ACC - report from ACC2024
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024
Late-Breaking Clinical Trials V - report from ACC2024
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV - report from ACC2024
Late Breaking Clinical Trial on interventional cardiology - report from ACC2024
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients - report from ACC2024
PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma? - report from ACC2024
ULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI - report from ACC2024
EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death - report from ACC2024
Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - report from ACC2024
Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials - report from ACC2024
Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock - report from ACC2024
Study Links E-Cigarette Use with Higher Risk of Heart Failure - report from ACC2024
Overall Survival Results of KEYNOTE-564
Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
Follicular Lymphoma highlights of the ASH 2023 Congress
Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023
Real-World Outcomes With Brexucabtagene Autoleucel - report from ASH2023
Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma - report from ASH2023
Present and future of Multiple Myeloma management - report from ASH2023
Highlights of the ASH 2023 Congress
Chronic Myeloid Leukemia: Novel Therapeutic Approaches - report from ASH2023
Acute myeloid leukemia highlights of ASH 2023 Congress
Chronic Myeloid Leukemia highlights of ASH 2023 Congress
Multiple Myeloma highlights of ASH 2023 Congress
Dramatically Worse Myeloma Outcomes in Real World vs. Trials - report from ASH2023
State of the art ALL treatement in 2023 - report from ASH2023
Acute myeloid leukemia highlights of the ASH 2023 Congress
Diagnostic and Therapeutic Novelties of Multiple Myeloma Management at ASH2023
Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress - report from ASH2023
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone Outperforms VRd Alone for Multiple Myeloma - report from ASH2023
Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia - report from ASH2023
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response - report from ASH2023
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL - report from ASH2023
Interpretable Artificial Intelligence Differentiates Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia - report from ASH2023
CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases - report from ASH2023
Medical Treatment of Renal Cell Carcinoma in 2023
Lung Cancer highlights of ESMO 2023 Congress
State of art lipid-lowering treatment in 2023
The importance of intensive lipid lowering in CV risk reduction: the role of early combination treatment
Lung cancer highlights of the ESMO 2023 Congress
Melanoma highlights of ESMO 2023 Congress
RCC highlights of ESMO 2023 Congress
Genitourinary cancer highlights of ESMO 2023 Congress
Breast Cancer highlights of the ESMO 2023 Congress
Treatment of mRCC in real world settings - report from ESMO2023
Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer - report from ESMO2023
Data Shows Survival Benefits with Tisotumab Vedotin in Cervical Cancer - report from ESMO2023
Late-breaking studies from ESMO 2023 - report from ESMO2023
KEYNOTE-942 mRNA-Based vaccine and novel techniques in the field of melanoma - report from ESMO2023
Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer - report from ESMO2023
Better use of existing drugs increases cervical cancer survival and reduces recurrence - report from ESMO2023
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer - report from ESMO2023
The CodeBreak 300 Trial in KRAS G12C-mutated mCRC - report from ESMO2023
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma - report from ESMO2023
Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC - report from ESMO2023
Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer - report from ESMO2023
PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - report from ESMO2023
Considerations of moderate asthma management - report from ERS2023
Heart Failure management in the post-COVID era - Lessons from the pandemic - report from ESC2023
Key points from the 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - report from ESC2023
Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19 - report from ESC2023
Burden of Cardiovascular Disease in the European Union - report from ESC2023
Highlights of ESC2023 Congress - Heart failure in focus - report from ESC2023
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the cardiologist's perspective - report from ESC2023
Main headlines of 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - report from ESC2023
STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity - report from ESC2023
When real-world data meet real patients' needs: how to optimally treat patients with chronic coronary syndromes in 2023? - report from ESC2023
OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis - report from ESC2023
2023 ESC Guidelines for the Management of Endocarditis - report from ESC2023
DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure - report from ESC2023
HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency - report from ESC2023
BUDAPEST CRT Upgrade: Cardiac resynchronisation therapy upgrade in heart failure with right ventricular pacing - a multicentre, randomised, controlled trial - report from ESC2023
2023 ESC Guidelines for the Management of Acute Coronary Syndromes - report from ESC2023
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the diabetologist's perspective - report from ESC2023
2023 ESC Guidelines for the Management of Cardiomyopathies - report from ESC2023
What is the optimal treatment of hypertension in diabetics? The ESH 2023 Hypertension Guidelines on Diabetes - report from ESH2023
Diabetes trials on SGLT2 and GLP1 and their effects on hypertension - report from ESH2023
The Rehabilitation of Beta-Blockers in the ESH Hypertension Guidelines - report from ESH2023
Hypertensive patients with diabetes: Are RAAS/Diuretic combinations the foundation of treatment? - report from ESH2023
Managing Hypertension in Real Practice: the New ESH2023 Hypertension Guidelines - report from ESH2023
Hyperuricemia in hypertensive patients - report from ESH2023
Hypertension in women - an underrecognized issue- report from ESH2023
What has changed in the new ESH Hypertension Guidelines? - report from ESH2023
When hypertension and dyslipidemia co-exist: How to decrease CV risk? - report from ESH2023
Hypertensive patients with heart disease: What should be the preferred combination? - report from ESH2023
Where is the role of triple combination in the management of hypertension? - report from ESH2023
The development of hypertension guidelines - report from ESH2023
”Ten Commandments” of Single Pill Combination Treatment in Hypertension - report from ESH2023
Beta-blockers in managing arterial hypertension - why, when and to whom? - report from ESH2023
Beyond the algorithm: What combination to choose in hypertension treatment? - report from ESH2023
Antihypertensive Drugs and Treatment Algorithms in the ESH2023 Hypertension Guidelines - report from ESH2023
Hypertension and kidney - the intricate relationship - report from ESH2023
Hot questions on blood pressure measurement in clinical practice - report from ESH2023
Significant LDL Cholesterol Reductions With ANGPTL3 siRNA in homozygous familial hypercholesterolaemia - report from EAS2023
HER2 treatment landscape 2023 - report from ESMO BC 2023
Do overweight and obesity confer an additional risk of CAD in patients with FH? - report from EAS2023
Objective assessement of skin disease severity with the help of AI
What's new in treatment of breast cancer? - Highlights of ESMO BC 2023
Hot topics in melanoma management - report from EADO2023
Functional Precision Medicine in Oncology - report from AACR2023
The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator - report from AACR2023
Current issues in the treatment of schizophrenia - report from EPA2023
Highlights of EPA 2023 - report from EPA2023
The Risk of Early Recurrent MI: What is the Role of Cholesterol Efflux and ApoA-I? - report from ACC2023
Bempedoic Acid Improves Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk - report from ACC2023
How to increase prescription of evidence-based therapies in adults with T2D and ASCVD? - The COORDINATE-Diabetes Study - report from ACC2023
The FREEDOM COVID Anticoagulation Strategy Randomized Trial - report from ACC2023
Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery - UK Mini Mitral Trial - report from ACC2023
Can Patients with Hypertrophic Cardiomyopathy do Vigorous Exercise? - A Multinational Lifestyle And Exercise Study - report from ACC2023
Efficacy and Safety of Oral PCSK9 Inhibitor, MK-0616 in the Treatment of Hypercholesterolemia - report from ACC2023
Transcatheter Edge-to-Edge Repair of Functional Mitral Regurgitation in Heart Failure - The COAPT Trial - report from ACC2023
Elevated Lipoprotein(a) as a Risk Enhancing Factor for Atherosclerotic Cardiovascular Disease - report from ACC2023
Sotatercept in combination with background therapy for the treatment of Pulmonary Arterial Hypertension — STELLAR Trial - report from ACC2023
The Omega-3 Mystery: New Evidence Supports the Therapeutic Value of EPA - report from ACC2023
LMWH use in pregnancy: The Highlow and the ALPINE trial - report from ASH2022
Treatment options for early, HR+, HER2- Breast Cancer - report from SABCS2022
Post neoadjuvant therapy in Triple Negative Breast Cancer - report from SABCS2022
Highlights of the San Antonio Breast Cancer Symposium 2022 - report from SABCS2022
Targeting CV risk factors with GLP-1 RAs in people with obesity - report from EASD2022
Once weekly insulin: The ONWARDS 2 study - report from EASD2022
Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction - report from EASD2022
Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg - report from EASD2022
Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022
Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising - report from EASD2022
Primary results of the phase 3 KEYNOTE-412 study - report from ESMO2022
Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma - report from ESMO2022
Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity - report from EASD2022
The IPSOS trial - report from ESMO2022
Choices in asthma and COPD care: How to maximize outcomes for patients - report from ERS2022
A fresh look at pulmonary hypertension: practical takeaways for patient management - report from ESC2022
Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial - report from ESC2022
Facing anticoagulation dilemmas in venous thromboembolism - report from ESC2022
The importance of optimal RAASi therapy in heart failure - report from ESC2022
Chronic coronary syndrome: re-thinking treatment management and outcome priorities - report from ESC2022
Dual antiplatelet therapy in practice - report from ESC2022
2022 ESC-ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - report from ESC2022
Guidelines in Practice: management of dyslipidaemias in the elderly - report from ESC2022
Guidelines in Practice: dual antiplatelet therapy (DAPT) - report from ESC2022
Getting to LDL-C goals and staying there long-term - report from ESC2022
Cardiorenal benefits of finerenone: protecting the heart and kidneys - report from ESC2022
The Journey to Address Unmet Needs Across all Haemophilia Indications - report from ISTH2022
Anticoagulant Advancements for VTE in Children - report from ISTH2022
Clinical Challenges in Patients with Venous Thromboembolism - report from ISTH2022
Good practice statements for antithrombotic therapy in the management of COVID-19 - report from ISTH2022
ISTH Proposal to Standardize Functional Assays in the Diagnosis of Heparin‐induced Thrombocytopenia - report from ISTH2022
Navigating the Joint Health Journey for Patients With Hemophilia - report from ISTH2022
Strategies for Assessing and Managing DOAC-Related Bleeding - report from ISTH2022
Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges - report from ISTH2022
Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism - report from ISTH2022
Roles of FVIII in Endothelial Cell Biology: More than a Coagulation Factor? - report from ISTH2022
Diagnosis and management of primary aldosteronism - report from ESH2022
Adherence to antihypertensive treatment in patients with CKD: a barrier to optimal renoprotection - report from ISTH2022
Brain cancers and the risk of intracranial hemorrhage with DOACs versus Low Molecular Weight Heparin - report from ISTH2022
Special forms of hypertension, optomized prevention and hypertension epidemiology - report from ESH2022
“Ten months of needles, we’d better get it right!” - The Highlow Study - report from ISTH2022
ISTH Guidelines for Anticoagulation in COVID-19 - report from ISTH2022
The SAXOPHONE Study - report from ISTH2022
Current Guidelines on Perioperative Anticoagulation Management: DOACs - report from ISTH2022
Diagnosis and management of non-adherence in hypertension treatment - report from ESH2022
Implementation of the 2019 lipid guidelines: where are we now? - report from EAS2022
Nocturnal hypertension - report from ESH2022
Blood pressure management in older frail patients - report from ESH2022
Lifelong burden of hypertension - report from ESH2022
New pathogenic insights in chronic urticaria - report from EADV Symposium 2022
Novelties in the diagnosis and management of primary aldosteronism - report from ESH2022
Results from the phase 3 PARADIGM trial - report from ASCO2022
Detecting elevated lipoprotein(a) and addressing the ASCVD risks - report from EAS2022
Who needs injectable therapies for cholesterol lowering or statins and ezetimibe are enough for CVD prevention? - report from EAS2022
Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials? - report from ASCO2022
The difference between the genetic and pharmacological inhibition of PCSK9 - report from EAS2022
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up - interview with Sibylle Loibl
Long-term efficacy and safety of ixekizumab - interview with Andrew Blauvelt
ESC/EAS joint session: What is new in secondary CV prevention?
ESC/EAS joint session: Advances in CV risk estimation with focus on dyslipidemia - report from EAS2022
Treatment options of chronic urticaria - report from EADV Symposium 2022
Novelties at the International Summit of Lung Cancer in Rome - report from ISLC2022 in Rome
Atrial fibrillation guidelines into clinical practice - report from EHRA2022
Recent developments of the conduction system pacing - report from EHRA2022
What do new guidelines tell us about conduction system pacing? - report from EHRA2022
Conduction system pacing: ready for prime time? - report from EHRA2022
Antithrombotic Approaches to Reduce the Risk of Secondary Event in CAD and PAD - report from ACC2022
Results from the EMPULSE Trial - report from ACC2022
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk - report from ACC2022
Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment - interview with Federico Cappuzzo
Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People - report from ACC2022
Protecting comorbid patients with atrial fibrillation from stroke - report from EHRA2022
How to reduce limb events including amputations in our patients? - report from ACC2022
Guidance in Heart Failure Care at ACC 2022 - report from ACC2022
EHRA scientific documents 2022 - report from EHRA2022
Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study - report from ACC2022
The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma - interview with David F. McDermott
How will the current therapeutic options change the treatment of RCC in the daily practice? - interview with Camillo Porta
Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma - interview with Stefan N. Symeonides
Treatment intensification in the treatment of prostate cancer - interview with Oliver Sartor
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer - interview with Ken Kato
State of the art treatment of bladder cancer - interview with Matthew R. Zibelman
Treatment of iron deficiency in acute and chronic heart failure - interview with Piotr Ponikowski
Alcohol septal ablation in hypertrophic cardiomyopathy: past and future - interview with Hubert Seggewiss
The use of SGLT2 inhibitors in the prevention and treatment of heart failure - interview with Petar Seferovic
Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era? - interview with Iacopo Olivotto
Diagnostic delay in pulmonary arterial hypertension - interview with Bodil Ivarsson and Barbro Kjellström
Clinical Impact of Liraglutide as a Treatment of Obesity - interview with Babak Dehestani
Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events - interview with Michael Camilleri
Novelties in the treatment of multiple myeloma 2021 - report from ASH2021
Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology - report from ASH2021
Novelties in the treatment of myelofibrosis and polycythemia vera 2021 - report from ASH2021
Highlights of the San Antonio Breast Cancer Symposium 2021 - report from SABCS2021
Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms - report from ASH2021
Final results of KEYNOTE-355 - report from SABCS2021
Results from the Randomized Phase 3 Transform Study - report from ASH2021
Novelties on the treatment of non-Hodgkin lymphoma - report from ASH2021
Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies - report from SABCS2021
PALLAS trial: Adjuvant palbociclib in HR+/HER2- early breast cancer - report from SABCS2021
The DESTINY-Breast03 trial - report from SABCS2021
Liraglutide for Weight Management in the Real World - interview with Roman Vangoitsenhoven
Clinical Impact of Liraglutide as a Treatment of Obesity - interview with Alexander Miras
The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction - interview with Michael Nauck
The role of SGLT2 inhibitors in the treatment of diabetes with cardiovascular disease - report from EASD2021
The current issues in Hypoglycaemia - report from EASD2021
Current guidelines on diabetes management - report from EASD2021
The MONALEESA-2 trial - report from ESMO2021
Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC) - report from ESMO2021
Should Cure Be A Reasonable Goal in aRCC? - report from ESMO2021
The Keynote 716 trial - report from ESMO2021
Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O? - report from ESMO2021
Highlights of the ESMO 2021 Congress - report from ESMO2021
Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB - report from ESMO2021
Metastases-free survival results from STAMPEDE - report from ESMO2021
Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB - report from ESMO2021
2021 ESC Guidelines - CVD Prevention - report from ESC2021
SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death - report from ESC2021
Antithrombin Deficiency Registry, an Update - report from ERS2021
ERS/EAACI statement on adherence to international adult asthma guidelines - report from ERS2021
Pulmonary hypertension and interstitial pulmonary fibrosis - report from ERS2021
The RIPCORD 2 trial - report from ESC2021
The STEP Study - report from ESC2021
2021 ESC Guidelines - Cardiac Pacing - report from ESC2021
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation - report from ESC2021
TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest - Valvular Heart Disease - report from ESC2021
2021 ESC Guidelines - Valvular Heart Disease - report from ESC2021
The APAF-CRT Trial - report from ESC2021
2021 ESC Guidelines - Cardiac Pacing - report from ESC2021
What is new about Angina? - report from ESC2021
LOOP Study: screening for AF with an implantable loop recorder to prevent stroke - report from ESC2021
2021 ESC Guidelines on Heart Failure - report from ESC2021
The SMART-MI Trial - report from ESC2021
Abelacimab for Prevention of Venous Thromboembolism - report from ISTH2021
State of the art treatment of breast cancer - report from ASCO2021
State of the art treatment of prostate cancer - report from ASCO2021
Clinical decision making in the treatment of melanoma - report from ASCO2021
Current state of immunotherapy options in the treatment of RCC - report from ASCO2021
Current state of immunotherapy options in the treatment of melanoma - report from ASCO2021
State of the art treatment of breast cancer - report from ASCO2021
The QUAZAR AML-001 Maintenance Trial - report from EHA 2021
Novelties in the treatment of Multiple Myeloma - report from EHA 2021
Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies - report from EHA 2021
Novelties in the treatment of follicular lymphoma - report from EHA 2021
Novelties on the treatment of Multiple Myeloma - report from EHA 2021
The evolution of hypertension management: The increasing role of triple therapy in clinical practice - report from ESH-ISH2021
20-years follow-up of ASCOT-legacy - report from ESH-ISH2021
ESH-ISH 2021 Late-Breakers Session - report from ESH-ISH2021
Important messages from EULAR2021: Impact of air pollution on RA flares, effect of COVID-19 on RA care, osteoporosis care of men - report from EULAR2021
Consequences of COVID-19 Outbreak on Mental Health - report from EPA2021
Meeting the challenges of schizophrenia care during the COVID-19 pandemic - report from EPA2021
Obstetric Complications: The Forgotten Risk Factor for Schizophrenia - report from EPA2021
Highlights of the EPA 2021 - report from EPA2021
Improving the management of hypertension: acting on key factors - report from ESH-ISH2021
The ISH 2020 global hypertension practice guidelines - report from ESH-ISH2021
Detailed summary of the Consensus Session of the SG-BCC 2021 - report from St. Gallen BCC 2021
PARADISE-MI: Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction - report from ACC2021
Hypertension Guidelines: Do They Vary Across the World as Much as My Blood Pressure Has Today - report from ACC2021
Care for patients with HER2-positive breast cancer - report from St. Gallen BCC 2021
Latest trends, developments in breast surgery - report from St. Gallen BCC 2021
Highlights of the 17th St. Gallen International Breast Cancer Conference - report from St. Gallen BCC 2021
The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer - report from St. Gallen BCC 2021
De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy - report from St. Gallen BCC 2021
Current state of frontline immunotherapy options in the treatment of NSCLC - report from ASCO2021
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma studies - report from EAU2021
Treatment of hematological malignancies in 2021 - report from EHA2021
Novelties in the treatment of chronic myeloid leukemia - report from EHA2021